Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Vignan Manne"'
Publikováno v:
Pathogens, Vol 10, Iss 12, p 1619 (2021)
The hepatitis C virus (HCV) is a common cause of chronic liver disease and liver cancer worldwide. Despite advances in curative therapies for HCV, the incidence of new infections is not decreasing at the expected rate to hit the World Health Organiza
Externí odkaz:
https://doaj.org/article/f0071ea830094cfaa09df7a455c8047e
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 20, Iss 5, Pp 279-287 (2014)
Cirrhosis affects millions of people throughout the world. Two of the most serious complications of liver cirrhosis are ascites and spontaneous bacterial peritonitis (SBP). The development of ascites is related to the severity of portal hypertension
Externí odkaz:
https://doaj.org/article/b10cf95db11f4de18836ca8a0b633b91
Publikováno v:
World Journal of Advanced Research and Reviews. 10:230-236
Only a few studies are available with appropriate data on the effects of non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with fatty liver disease. We performed a retrospective study of 1347 patients with imaging studies th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f8a411edaebbf9c1eea263dcb7cc45
https://doi.org/10.30574/wjarr.2021.10.1.0165
https://doi.org/10.30574/wjarr.2021.10.1.0165
Autor:
Kris V. Kowdley, Vignan Manne
Publikováno v:
Clinics in Liver Disease. 24:483-492
Alpha1-antitrypsin deficiency (A1ATD) is an inherited cause of chronic liver disease. It is inherited in an autosomal codominant pattern with each inherited allele expressed in the formation of the final protein, which is primarily produced in hepato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb469b3969cf3bb4c7948c10edac7c5b
https://doi.org/10.1016/j.cld.2020.04.010
https://doi.org/10.1016/j.cld.2020.04.010
Autor:
Vignan Manne, Kris V. Kowdley
Publikováno v:
Current Opinion in Gastroenterology. 35:191-196
This review will summarize the use of obeticholic acid (OCA) in treatment of primary biliary cholangitis (PBC). It seeks to discuss the mechanism of action, evidence for use, appropriate clinical use, and common adverse effects of OCA.PBC is a chroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c33b0d97d847f56e4694767f101aea85
https://doi.org/10.1097/mog.0000000000000525
https://doi.org/10.1097/mog.0000000000000525
Autor:
Nizar H. Senussi, Vignan Manne
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 20(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867544bf9ed8c062145224be61e3122c
https://pubmed.ncbi.nlm.nih.gov/32858202
https://pubmed.ncbi.nlm.nih.gov/32858202
Autor:
Vignan, Manne, Kris V, Kowdley
Publikováno v:
Clinics in liver disease. 24(3)
Alpha1-antitrypsin deficiency (A1ATD) is an inherited cause of chronic liver disease. It is inherited in an autosomal codominant pattern with each inherited allele expressed in the formation of the final protein, which is primarily produced in hepato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::208226558bb4af2ba82c6f3ec04207d9
https://pubmed.ncbi.nlm.nih.gov/32620284
https://pubmed.ncbi.nlm.nih.gov/32620284
Publikováno v:
Clinics in Liver Disease. 22:23-37
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH) and ultimately may lead to cirrhosis. Hepatic steatosis or fatty liver is defined as increased ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6395f7500c262aead8e69a35e33e0343
https://doi.org/10.1016/j.cld.2017.08.007
https://doi.org/10.1016/j.cld.2017.08.007
Autor:
Lisa Finch, Vignan Manne, Rubal Penna, Manan A. Jhaveri, Kris V. Kowdley, Eric Gochanour, Nizar H. Senussi
Publikováno v:
Gastroenterology. 158:S-1385
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fccd35e611c56c49a7b739a3a48876e2
https://doi.org/10.1016/s0016-5085(20)34132-9
https://doi.org/10.1016/s0016-5085(20)34132-9
Publikováno v:
Drugsaging. 35(2)
Since the introduction of direct-acting antivirals (DAAs), the outcomes of hepatitis C (HCV) treatment have shown an improvement in cure rates with minimal side effects. However, to date, the safety and efficacy of DAAs have not been specifically exa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90243a18a1e0a157cb486e5777cd871d
https://pubmed.ncbi.nlm.nih.gov/29417462
https://pubmed.ncbi.nlm.nih.gov/29417462